DiscoverHaemcastBeyond approval | Considerations and Challenges in Access to Gene Therapy featuring Nicola Redfern
Beyond approval | Considerations and Challenges in Access to Gene Therapy featuring Nicola Redfern

Beyond approval | Considerations and Challenges in Access to Gene Therapy featuring Nicola Redfern

Update: 2022-11-28
Share

Description

In this episode of Haemcast, host Dr Kate Khair speaks with Nicola Redfern, former UK General Manager and Northern European cluster lead at bluebird bio and experienced leader in the biopharmaceutical industry, having worked across oncology, rare diseases and ATMPs. We discuss the considerations and challenges when it comes to access of gene therapies, and what the bleeding disorders community can do to ensure these innovative treatments are accepted by payers and become a real option for patients.


Connect with Nicola on LinkedIn


Comments or questions about the show? Connect with us on Twitter and LinkedIn or send us a line to hello@haemnet.com

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Beyond approval | Considerations and Challenges in Access to Gene Therapy featuring Nicola Redfern

Beyond approval | Considerations and Challenges in Access to Gene Therapy featuring Nicola Redfern

Haemnet